A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

3.0.0 161 2022-11-15T16:33:13Z 2022-11-15T16:33:13Z House H HRES 2013-04-15 113 hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2013-04-19T20:06:35Z Referred to 2013-04-15T16:02:40Z A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs. 113 97 SRES 2013-04-15 Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654) Related bill CRS 2013-04-19 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2013-04-15 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2013-04-15 Introduced in House IntroReferral Intro-H 9 Library of Congress 2013-04-15 Introduced in House IntroReferral 1000 9 Library of Congress R000395 Rep. Rogers, Harold [R-KY-5] HAROLD ROGERS R KY 5 N K000375 Rep. Keating, William R. [D-MA-9] William Keating D MA R. 9 2013-04-15 True W000672 Rep. Wolf, Frank R. [R-VA-10] FRANK WOLF R VA R. 10 2013-04-15 True R000011 Rep. Rahall, Nick J., II [D-WV-3] NICK RAHALL D WV J. 3 2013-04-15 True G000569 Rep. Grimm, Michael G. [R-NY-11] Michael Grimm R NY G. 11 2013-04-15 True L000562 Rep. Lynch, Stephen F. [D-MA-8] Stephen Lynch D MA F. 8 2013-04-15 True T000266 Rep. Tierney, John F. [D-MA-6] JOHN TIERNEY D MA F. 6 2013-04-15 True A000055 Rep. Aderholt, Robert B. [R-AL-4] ROBERT ADERHOLT R AL B. 4 2013-04-15 True Health Drug safety, medical device, and laboratory regulation Drug, alcohol, tobacco use Prescription drugs Health

00 2013-04-15 Introduced in House 2013-05-16T15:16:43Z Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

]]>

Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs. Display Title Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs. Official Title as Introduced Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs. Introduced in House 2013-04-15T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-113hres161ih/xml/BILLS-113hres161ih.xml 2013-04-19 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.